Philip Siberg
Chief Executive Officer
Q1 report 2026 presentation
Philip Siberg, CEO of Senzime, will present the report for Q1 2026 on April 22, 9:00 CEST.
Presentation
CEO Philip Siberg presents the report.
Safeguarding patients during anesthesia and recovery
Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).
Press release
Senzime’s TetraGraph System Contracted on Three Leading GPO Agreements in the US
Regulatory PR
Senzime publishes annual and sustainability report for 2025
Regulatory PR
Margins strengthened and cash flow improved despite a temporary dip in the growth trajectory. Full-year targets remain on track.
Financial info Jan - Mar 2026
Margins strengthened and cash flow improved despite a temporary dip in the growth trajectory. Full-year targets remain on track.
2026 has started at a strong pace, with improved margins and solid cash flow generation. However, the US market experienced delays in contract processes during the quarter, which combined with a stronger Swedish krona led to a temporary dip in the growth trajectory.
Despite this, our 2026 targets remain intact with continued strong full-year growth and profitability by the end of the year.
23,233
KSEK, Net sales
40
%, Growth of sensor sales in constant currencies
33
%, Operating cash flow improvement
69,2
%, Underliggande bruttomarginal
Subscribe
Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities.